[FG] Kappos Ludwig

Callegari, Ilaria et al. (2026) ‘An online tool to facilitate the application of 2024 McDonald criteria.’, ECTRIMS. Toronto (ECTRIMS), 21 October.

Kaim, K. et al. (2026) ‘Macro- and microstructural changes in the upper cervical spinal cord and their clinical correlates in multiple sclerosis’, Multiple Sclerosis Journal – Experimental, Translational and Clinical, 12(4). Available at: https://doi.org/10.1177/20552173261479426.

Piot, Ines et al. (2026) ‘Endovascular therapy in acute ischaemic stroke patients with prestroke dependency-an EVA-TRISP cohort study’, European Stroke Journal, 11. Available at: https://doi.org/10.1093/esj/aakag099.

Altersberger, Valerian L. et al. (2026) ‘Anemia and elevated hemoglobin in stroke patients treated with thrombectomy – a cohort study from the EndoVAscular treatment and ThRombolysis for Ischemic Stroke Patients collaboration’, Journal of Thrombosis and Haemostasis, 24(8), pp. 3030–3040. Available at: https://doi.org/10.1016/j.jtha.2026.05.004.

Butzkueven, H. et al. (2026) ‘Tysabri Observational Program (TOP): long-term safety and effectiveness of natalizumab treatment in relapsing-remitting multiple sclerosis over 15 years’, Journal of Neurology, Neurosurgery & Psychiatry, 97(7), pp. 591–599. Available at: https://doi.org/10.1136/jnnp-2025-337367.

Iaquinto, Stefania et al. (2026) ‘Incidence of multiple sclerosis in Switzerland – results from the Swiss multiple sclerosis registry’, Multiple Sclerosis and Related Disorders, 111. Available at: https://doi.org/10.1016/j.msard.2026.107239.

Liegeois, Clémence et al. (2026) ‘Tenecteplase or alteplase for acute ischemic stroke beyond 4.5 hours of last known well: A pooled analysis of the TETRIS and EVATRISP registries’, International Journal of Stroke, 21(5), pp. 667–675. Available at: https://doi.org/10.1177/17474930251385744.

Schwartzmann, Yoel et al. (2026) ‘Characteristics of Unsuccessful Recanalization Following Endovascular Thrombectomy: Cohort Study (EVATRISP Collaboration)’, Stroke, Publish Ahead of Print. Available at: https://doi.org/10.1161/STROKEAHA.125.055002.

Mayer-Suess, L. et al. (2026) ‘Safety of Endovascular Thrombectomy in Isolated Cervical Internal Carotid Artery Occlusion While on Oral Anticoagulation’, Journal of Stroke, 28(2), pp. 321–325. Available at: https://doi.org/10.5853/jos.2025.05918.

Boos, Lukas et al. (2026) ‘ESTREL-Fatigue—association of levodopa with post-stroke fatigue’, European Stroke Journal, 11. Available at: https://doi.org/10.1093/esj/aakag029.

Wagner, Benjamin et al. (2026) ‘Diagnostic accuracy of gray-scale analysis on B-mode ultrasound for identifying intraplaque hemorrhage and lipid-rich necrotic core in carotid plaques’, Vascular Medicine United Kingdom, 31(2), pp. 175–184. Available at: https://doi.org/10.1177/1358863x251410527.

Jost, Jasmine et al. (2026) ‘Safety of endovascular therapy in ischemic stroke patients ⩾90 years: A cohort study from the EVA-TRISP collaboration’, European Stroke Journal, 11. Available at: https://doi.org/10.1093/esj/23969873251360607.

Schwartzmann, Yoel et al. (2026) ‘FRET score: predictors of futile recanalisation following endovascular thrombectomy—a multicentre cohort study from the EVATRISP collaboration’, European Stroke Journal, 11. Available at: https://doi.org/10.1093/esj/aakaf013.

Sauter, Mirjam I. et al. (2026) ‘The impact of levodopa on post-stroke depression: the ESTREL-depression-study’, European Stroke Journal, 11. Available at: https://doi.org/10.1093/esj/aakag001.

Wali, N. et al. (2026) ‘Admission Systolic Blood Pressure and Outcomes After Endovascular Thrombectomy’, Neurology, 106(3). Available at: https://doi.org/10.1212/wnl.0000000000214530.

Benci, Zeno et al. (2026) ‘Previous Antiplatelet Therapy and Outcomes of Acute Ischemic Stroke With Large Vessel Occlusion Treated With Direct Endovascular Therapy’, Neurology, 106. Available at: https://doi.org/10.1212/WNL.0000000000214672.

Calabresi, P.A. et al. (2026) ‘Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial’, Multiple Sclerosis Journal, 32(1), pp. 107–120. Available at: https://doi.org/10.1177/13524585251396433.

Chen, Xinjie et al. (2026) ‘Cross-site quantitative MRI harmonization: The impact on age modeling in health and disease’, Imaging Neuroscience. 30.01.2026, 4. Available at: https://doi.org/10.1162/IMAG.a.1140.

Girfanova, Maria et al. (2026) ‘Endovascular Treatment in Patients With Acute Ischemic Stroke and Intracranial Stenting: A Cohort Study of EVA-TRISP Collaboration’, Acta Neurologica Scandinavica, 2026. Available at: https://doi.org/10.1155/ane/6300825.

Honegger, F. et al. (2026) ‘Vestibular agnosia in elderly subjects with small vessel disease and imbalance – preliminary results from an ongoing prospective study’, in 12th Congress of the European Academy of Neurology, Geneva, 2026. Genf (12th Congress of the European Academy of Neurology, Geneva, 2026).

Maceski, Aleksandra Maleska (2026) Development of glial fibrillary acidic protein (GFAP) as a biomarker for multiple sclerosis progression and identification of novel progression-related proteins. Doctoral Thesis. University of Basel.

Mastantuono, M. et al. (2026) ‘Choroid plexus morphological and microstructural changes across inflammatory phenotypes in multiple sclerosis’, Multiple Sclerosis Journal [Preprint]. Available at: https://doi.org/10.1177/13524585261462513.

Riegler, Christoph et al. (2026) ‘Emergent Carotid Stenting During Endovascular Therapy for Isolated Cervical Internal Carotid Artery Occlusion’, Journal of Stroke, 28(1), pp. 160–171. Available at: https://doi.org/10.5853/jos.2025.04098.

Salerno, A. et al. (2026) ‘Outcomes and Safety of Revascularization Approaches for Stroke Related to Isolated Vertebral Artery Occlusions (BRAVO)’, Stroke, Publish Ahead of Print. Available at: https://doi.org/10.1161/strokeaha.125.051675.

Spagnolo, Federico et al. (2026) ‘Beyond EDSS: Subscores and FS Trajectories Reveal Hidden Disability Dynamics in Secondary Progressive Multiple Sclerosis’, ECTRIMS.

Sværke, K. et al. (2026) ‘Long-term mental health and quality of life in patients after cervical artery dissection’, Frontiers in Neurology, 17. Available at: https://doi.org/10.3389/fneur.2026.1726823.

Trüssel, Simon et al. (2026) ‘Time course of motor recovery after stroke with and without levodopa: a post hoc 6-month longitudinal analysis of the ESTREL trial’, European Stroke Journal, 11. Available at: https://doi.org/10.1093/esj/aakag089.

Noseda, Roberta et al. (2025) ‘Sex differences in outcomes after endovascular therapy with prior antiplatelet use: A study from the EVA-TRISP registry’, European Stroke Journal, 10(4), pp. 1300–1311. Available at: https://doi.org/10.1177/23969873251346016.

Maceski, Aleksandra Maleska et al. (2025) ‘GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis’, Brain [Preprint]. Available at: https://doi.org/10.1093/brain/awaf433.

Engelter, Stefan T. et al. (2025) ‘Levodopa Added to Stroke Rehabilitation: The ESTREL Randomized Clinical Trial’, JAMA, 334, pp. 1523–1532. Available at: https://doi.org/10.1001/jama.2025.15185.

Lieschke, Simone et al. (2025) ‘Revascularization Treatment of Basilar Artery Occlusion in Patients with Mild‐to‐Moderate Severe Stroke’, Stroke: Vascular and Interventional Neurology, 5(6). Available at: https://doi.org/10.1161/svin.125.002059.

Olivieri, Emanuele, Müller, Jannis and Toosy, Ahmed T. (2025) ‘Predicting Disability Using PIRA in Multiple Sclerosis: Is It as Straightforward as It Appears?’, Neurology, 105, p. e214206. Available at: https://doi.org/10.1212/wnl.0000000000214206.

Kappos, L. et al. (2025) ‘Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial’, Multiple Sclerosis and Related Disorders, 102, p. 106616. Available at: https://doi.org/10.1016/j.msard.2025.106616.

Callegari, Ilaria et al. (2025) ‘Ultra-High Field MRI-Based Myelin Water Fraction supports the identification of Active Remyelination in MS Post-Mortem Brains’, in Multiple Sclerosis Journal. Barcelone, Spain: SAGE Publications Ltd (41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis), pp. 1061–1062.

Berati, Kristel et al. (2025) ‘Somatosensory Profile of Central Post Stroke Pain of Thalamic Origin: Findings of a Quantitative Sensory Testing Study’, European Journal of Pain. 15.08.2025, 29(8). Available at: https://doi.org/10.1002/ejp.70104.

Cohen, J.A. et al. (2025) ‘Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials’, Multiple Sclerosis Journal, 31(10), pp. 1218–1230. Available at: https://doi.org/10.1177/13524585251355842.

Engelter, Stefan T et al. (2025) ‘The 6-months follow-up of the TREAT-CAD trial: Aspirin versus anticoagulation for stroke prevention in patients with cervical artery dissection’, European Stroke Journal, 10, pp. 871–881. Available at: https://doi.org/10.1177/23969873251315362.

Galbusera, Riccardo et al. (2025) ‘Quantitative T1 is sensitive to cortical remyelination in multiple sclerosis: A postmortem MRI study’, Brain Pathology. 14.04.2025, 35(5). Available at: https://doi.org/10.1111/bpa.70010.

Marto, João Pedro et al. (2025) ‘Endovascular treatment for isolated cervical internal carotid artery occlusion: ETIICA study’, European Stroke Journal, 10(3), pp. 694–704. Available at: https://doi.org/10.1177/23969873251323488.

Einsiedler, Maximilian et al. (2025) ‘Treatment Strategies and Disease Activity During Pregnancy and Postpartum’, Neurology Clinical Practice, 15(4). Available at: https://doi.org/10.1212/cpj.0000000000200499.

Fischer, Sandro K. et al. (2025) ‘Long-Term Risk of Recurrent Cervical Artery Dissection and Stroke After Pregnancy’, JAMA Network Open, 8. Available at: https://doi.org/10.1001/jamanetworkopen.2025.21539.

Kuhlmann, Jenni et al. (2025) ‘Music therapy with a monochord in multiple sclerosis (“MUTIMS”): A randomized, controlled, rater-blinded trial’, Multiple Sclerosis Journal Experimental Translational and Clinical, 11. Available at: https://doi.org/10.1177/20552173251352712.

Montobbio, Noemi et al. (2025) ‘Uncovering a bias in estimated treatment effects on PIRA in multiple sclerosis clinical trials’, Ebiomedicine, 117. Available at: https://doi.org/10.1016/j.ebiom.2025.105802.

Müller, Jannis et al. (2025) ‘Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis’, JAMA Neurology. 14.04.2025, 82(6), pp. 614–625. Available at: https://doi.org/10.1001/jamaneurol.2025.0495.

Arnold, Douglas L et al. (2025) ‘Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS’, Multiple Sclerosis Journal, 31(7), pp. 821–832. Available at: https://doi.org/10.1177/13524585251325086.

Bovis, Francesca et al. (2025) ‘Personalized Treatment Response in Progressive MS: Can the Patient’s Profile Influence the Outcome?’, Brain and Behavior, 15(6). Available at: https://doi.org/10.1002/brb3.70459.

Harris, Sarah et al. (2025) ‘Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials’, European Journal of Neurology, 32(6). Available at: https://doi.org/10.1111/ene.70222.

Kappos, Ludwig et al. (2025) ‘Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials’, Neurology, 104(10). Available at: https://doi.org/10.1212/wnl.0000000000213558.

Androdias, Géraldine et al. (2025) ‘De-escalating and discontinuing disease-modifying therapies in multiple sclerosis’, Brain, 148(5), pp. 1459–1478. Available at: https://doi.org/10.1093/brain/awae409.

Damiano, Marastoni et al. (2025) ‘Intrathecal Inflammatory Profile and Gray Matter Damage Predict Progression Independent of Relapse Activity in Early Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 12(4), p. e200399. Available at: https://doi.org/10.1212/nxi.0000000000200399.

Mallucci, Giulia et al. (2025) ‘Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to assess EDSS for decentralized trials in multiple sclerosis’, Multiple Sclerosis Journal. 20.12.2024, 31(4), pp. 497–501. Available at: https://doi.org/10.1177/13524585241305966.

Müller, Jannis et al. (2025) ‘Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study’, CNS Drugs, 39(4), pp. 403–416. Available at: https://doi.org/10.1007/s40263-025-01164-w.

Muraro, Paolo A. et al. (2025) ‘Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT’, Nature Reviews Neurology. 15.01.2025, 21(3), pp. 140–158. Available at: https://doi.org/10.1038/s41582-024-01050-x.

Ralph, Hb Benedict et al. (2025) ‘Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials’, Multiple Sclerosis and Related Disorders, 95. Available at: https://doi.org/10.1016/j.msard.2025.106310.

Greselin, Martina et al. (2025) ‘AI-driven detection of distinct disability Patterns within equivalent EDSS Scores’, Day of Clinical Research, Department of Clinical Research, University of Basel. Basel (Day of Clinical Research, Department of Clinical Research, University of Basel), 6 February.

Benci, Z. et al. (2025) ‘Abstract WP240: Prior Antiplatelet Therapy Improves Functional Outcomes in Acute Ischemic Stroke Patients Undergoing Direct Mechanical Thrombectomy’, Stroke, 56(Suppl_1). Available at: https://doi.org/10.1161/str.56.suppl_1.wp240.

Patrick, Vermersch et al. (2025) ‘Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy’, Multiple Sclerosis and Related Disorders, 94, p. 106259. Available at: https://doi.org/10.1016/j.msard.2025.106259.

Pless, Silvan et al. (2025) ‘CoGames: Development of an adaptive smartphone-based and gamified monitoring tool for cognitive function in Multiple Sclerosis’, Journal of Neurology, 272(2). Available at: https://doi.org/10.1007/s00415-024-12818-y.

Oechtering, Johanna et al. (2025) ‘Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 12(2). Available at: https://doi.org/10.1212/nxi.0000000000200361.

Benkert, Pascal et al. (2025) ‘Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis’, Annals of Neurology. 16.10.2024, 97(1), pp. 104–115. Available at: https://doi.org/10.1002/ana.27096.

Gordaliza, Pedro M. et al. (2025) ‘Fluid and White Matter Suppression contrasts MRI improves Deep Learning detection of Multiple Sclerosis Cortical Lesions’, Neuroimage Clinical, 48. Available at: https://doi.org/10.1016/j.nicl.2025.103818.

Jost, Jasmine et al. (2025) ‘Safety of endovascular therapy in ischemic stroke patients ⩾90 years: A cohort study from the EVA-TRISP collaboration’, European Stroke Journal [Preprint]. Available at: https://doi.org/10.1177/23969873251360607.

Marto, João Pedro et al. (2025) ‘Recanalization Outcomes and Procedural Complications in Patients With Acute Ischemic Stroke and COVID-19 Receiving Endovascular Treatment’, Journal of Stroke, 27(1), pp. 128–132. Available at: https://doi.org/10.5853/jos.2024.04077.

Müller, Jannis, Derfuss, Tobias and Yaldizli, Özgür (2025) ‘Klinische Grundlagen der MS’, in Multiple Sklerose verstehen und behandeln. Springer (Multiple Sklerose verstehen und behandeln).

Pontillo, Giuseppe et al. (2025) ‘More Than the Sum of Its Parts: Disrupted Core Periphery of Multiplex Brain Networks in Multiple Sclerosis’, Human Brain Mapping, 46(1). Available at: https://doi.org/10.1002/hbm.70107.

Sharmin, Sifat et al. (2025) ‘MSoutcomes: CORe Multiple Sclerosis Outcomes Toolkit’. Available at: https://doi.org/https://CRAN.R-project.org/package=MSoutcomes.

Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial’, Trials. 11.09.2024, 25(1). Available at: https://doi.org/10.1186/s13063-024-08454-6.

Oh, J. et al. (2024) ‘Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study’, Scientific Reports, 14(1). Available at: https://doi.org/10.1038/s41598-023-49299-4.

Zietz, Annaelle et al. (2024) ‘Enhancement of STroke REhabilitation with Levodopa (ESTREL): Rationale and design of a randomized placebo-controlled, double blind superiority trial’, European Stroke Journal, 9(4), pp. 1093–1102. Available at: https://doi.org/10.1177/23969873241255867.

Montalban, Xavier et al. (2024) ‘Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials’, The Lancet Neurology. 19.09.2024, 23(11), pp. 1119–1132. Available at: https://doi.org/10.1016/s1474-4422(24)00328-4.

Woelfle, Tim et al. (2024) ‘Benchmarking Human–AI collaboration for common evidence appraisal tools’, Journal of Clinical Epidemiology. 12.09.2024, 175. Available at: https://doi.org/10.1016/j.jclinepi.2024.111533.

Greselin, Martina et al. (2024) ‘The contribution of Neurostatus subscore-tests to the Functional System Scores and Expanded Disability Status Scale levels’, ECTRIMS. Kopenhagen (ECTRIMS), 18 September.

Cagol, Alessandro et al. (2024) ‘Advanced Quantitative MRI Unveils Microstructural Thalamic Changes Reflecting Disease Progression in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 11(6). Available at: https://doi.org/10.1212/nxi.0000000000200299.

Müller, Jannis et al. (2024) ‘Quantifying Remyelination Using χ-Separation in White Matter and Cortical Multiple Sclerosis Lesions’, Neurology. 30.08.2024, 103(6). Available at: https://doi.org/10.1212/wnl.0000000000209604.

Cortese, Rosa et al. (2024) ‘Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis’, Annals of Neurology, 96(2), pp. 276–288. Available at: https://doi.org/10.1002/ana.26951.

Sastre-Garriga, J. et al. (2024) ‘Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives’, Neurology, 103(3). Available at: https://doi.org/10.1212/wnl.0000000000209677.

Kappos, L. et al. (2024) ‘Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial’, Journal of Neurology, 271(7), pp. 4599–4609. Available at: https://doi.org/10.1007/s00415-024-12417-x.

Ciccarelli, O. et al. (2024) ‘Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis’, Neurology, 103(1). Available at: https://doi.org/10.1212/wnl.0000000000209444.

Kaufmann, Josefin E. et al. (2024) ‘Antithrombotic Treatment for Cervical Artery Dissection: A Systematic Review and Individual Patient Data Meta-Analysis’, JAMA Neurology. 13.05.2024, 81(6), pp. 630–637. Available at: https://doi.org/10.1001/jamaneurol.2024.1141.

Chitnis, T. et al. (2024) ‘Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS’, Multiple Sclerosis Journal, 30(7), pp. 833–842. Available at: https://doi.org/10.1177/13524585241242050.

Diem, L et al. (2024) ‘Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers’, Multiple Sclerosis and Related Disorders, 86. Available at: https://doi.org/10.1016/j.msard.2024.105570.

Hirt, Julian et al. (2024) ‘Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis’, Journal of Neurology, 271(6), pp. 3131–3141. Available at: https://doi.org/10.1007/s00415-024-12366-5.

Wendebourg, Maria Janina et al. (2024) ‘Cervical and thoracic spinal cord gray matter atrophy is associated with disability in patients with amyotrophic lateral sclerosis’, European Journal of Neurology, 31(6). Available at: https://doi.org/10.1111/ene.16268.

Kaufmann, Josefin E. et al. (2024) ‘Toward Individual Treatment in Cervical Artery Dissection: Subgroup Analysis of the TREAT-CAD Randomized Trial’, Annals of Neurology. 16.02.2024, 95(5), pp. 886–897. Available at: https://doi.org/10.1002/ana.26886.

Khalil, Michael et al. (2024) ‘Neurofilaments as biomarkers in neurological disorders — towards clinical application’, Nature Reviews Neurology, 20(5), pp. 269–287. Available at: https://doi.org/10.1038/s41582-024-00955-x.

Müller, Jannis et al. (2024) ‘Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis’, Brain and Behavior. 30.04.2024, 14(5). Available at: https://doi.org/10.1002/brb3.3498.

Papadopoulou, Athina et al. (2024) ‘Visual evoked potentials in multiple sclerosis: P100 latency and visual pathway damage including the lateral geniculate nucleus’, Clinical Neurophysiology. 20.02.2024, 161, pp. 122–132. Available at: https://doi.org/10.1016/j.clinph.2024.02.020.

Fox, R.J. et al. (2024) ‘Temporal Relationship between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients with Multiple Sclerosis’, Neurology, 102(9). Available at: https://doi.org/10.1212/wnl.0000000000209357.

Weigel, Matthias et al. (2024) ‘Cerebellar Ex Vivo Magnetic Resonance Imaging at its Feasibility Limit: Up to 77-Microns Isotropic Resolution using Low-Bandwidth Balanced Steady State Free Precession (LoBa-bSSFP) Sequences and 3T Standard Equipment’, bioRxiv (Cold Spring Harbor Laboratory) [Preprint]. Cold Spring Harbor Laboratory (bioRxiv (Cold Spring Harbor Laboratory)). Available at: https://doi.org/10.1101/2024.04.18.589707.

Hirt, Julian et al. (2024) ‘Use of pragmatic randomized trials in multiple sclerosis: A systematic overview’, Multiple Sclerosis Journal, 30(4-5), pp. 463–478. Available at: https://doi.org/10.1177/13524585231221938.

Lazzarotto, A. et al. (2024) ‘Time is myelin: early cortical myelin repair prevents atrophy and clinical progression in multiple sclerosis’, Brain, 147(4), pp. 1331–1343. Available at: https://doi.org/10.1093/brain/awae024.

Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1- A Pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in Multiple Sclerosis: a study protocol for a randomized clinical trial’, medRxiv (Cold Spring Harbor Laboratory) [Preprint]. Cold Spring Harbor Laboratory (medRxiv (Cold Spring Harbor Laboratory)). Available at: https://doi.org/10.1101/2024.03.22.24304720.

Callegari, Ilaria et al. (2024) ‘Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5’, Brain, 147(3), pp. 839–848. Available at: https://doi.org/10.1093/brain/awad424.

Gloor, Monika et al. (2024) ‘Longitudinal analysis of new multiple sclerosis lesions with magnetization transfer and diffusion tensor imaging’, European Radiology. 02.09.2023, 34(3), pp. 1680–1691. Available at: https://doi.org/10.1007/s00330-023-10173-6.

Oechtering, Johanna et al. (2024) ‘Complement Activation Is Associated With Disease Severity in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 11(2). Available at: https://doi.org/10.1212/nxi.0000000000200212.

Kappos, Ludwig et al. (2024) ‘Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension’, Journal of Neurology, 271(2), pp. 642–657. Available at: https://doi.org/10.1007/s00415-023-11943-4.

Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/wnl.0000000000207768.

Wilson, David et al. (2024) ‘Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury’, Clinical Chemistry and Laboratory Medicine, 62(2), pp. 322–331. Available at: https://doi.org/10.1515/cclm-2023-0518.

Derfuss, Tobias et al. (2024) ‘Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials’, Therapeutic Advances in Neurological Disorders, 17. Available at: https://doi.org/10.1177/17562864241277736.

Filioglo, Andrei et al. (2024) ‘Corrigendum: Tandem occlusions involving the internal carotid and anterior cerebral arteries—A rare form of stroke: results from the multicenter EVATRISP collaboration study (Frontiers in Neurology, (2022), 13, (1024891), 10.3389/fneur.2022.1024891)’, Frontiers in Neurology , 15. Available at: https://doi.org/10.3389/fneur.2024.1450372.